Xencor, Inc. (XNCR) Stock Grade

About Xencor, Inc.'s fundamentals

Xencor is a biotechnology company with a market capitalization of $1.1 billion that generated 13.7% year-over-year revenue growth in its latest period. However, the company operates at a significant loss, with a net margin of -73.2%, and reported a net loss in its most recent annual statement. The company does not pay a dividend and has not yet achieved profitability. As a development-stage biotech firm, Xencor's financial metrics reflect the typical profile of companies investing heavily in research and drug development prior to commercial success.